Advertisement

Antibacterial Agents

Chapter

Abstract

Traditionally, antipseudomonal penicillins combined with an aminoglycoside have been the standard choice for the initial therapy of fever and neutropenia. These regimens were covering primarily Enterobacteriaceae, Pseudomonas aeruginosa, and streptococci. The activity of the former antipseudomonal penicillins (such as carbenicillin, cefsulodin, azlocillin, and ticarcillin) against many Gram-negative rods was, however, rather limited, and the addition of an aminoglycoside was needed to compensate for this limited activity. In the 1980s, ceftazidime was one of the first drugs studied as monotherapy in febrile neutropenia. It was more active in vitro against P. aeruginosa than most of the penicillins and highly active against Escherichia coli and Klebsiella species.

Keywords

Minimum Inhibitory Concentration Clostridium Difficile Infection Clavulanic Acid Carbapenem Resistance Febrile Neutropenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ackerman BH, Patton ML, Guilday RE, et al. Trimethoprim-induced hyperkalemia in burn patients treated with intravenous or oral trimethoprim sulfamethoxazole for methicillin-resistant Staphylococcus aureus and other infections: nature or nurture? J Burn Care Res. 2013;34:127–32.PubMedGoogle Scholar
  2. 2.
    Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2000;16:5–15.PubMedGoogle Scholar
  3. 3.
    Ariano RE, Nyhlén A, Donnelly JP, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005;39:32–8.PubMedGoogle Scholar
  4. 4.
    Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–35.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Baglie S, Rosalen PL, Franco LM, et al. Comparative bioavailability of 875 mg amoxicillin tablets in healthy human volunteers. Int J Clin Pharmacol Ther. 2005;43:350–4.PubMedGoogle Scholar
  6. 6.
    Berry V, Thorburn CE, Knott SJ, et al. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother. 1998;42:3193–9.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Berthoin K, Le Duff CS, Marchand-Brynaert J, et al. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother. 2010;65:1073–5.PubMedGoogle Scholar
  8. 8.
    Blaser J, König C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis. 1995;14:1029–38.PubMedGoogle Scholar
  9. 9.
    Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005;49(9):3944–7.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother. 2014;58:2334–43.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Bookstaver PB, Johnson JW, McCoy TP, et al. Modification of diet in renal disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination. Ann Pharmacother. 2008;42:1758–65.PubMedGoogle Scholar
  12. 12.
    Bow EJ. Point: fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined outcomes in defined populations, but must be used wisely. J Natl Compr Canc Netw. 2004;2(5):433–44.PubMedGoogle Scholar
  13. 13.
    Boyer A, Gruson D, Bouchet S, et al. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf. 2013;36:217–30.PubMedGoogle Scholar
  14. 14.
    Bubalo JS, Munar MY, Cherala G, et al. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53:428–34.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Bucaneve G, Miccozzi A, for the GIMEMA Infection Program. Prospective, randomised, multicentre controlled trial on empiric antibiotic therapy in febrile neutropenic cancer patients: piperacillin and tazobactam plus tigecycline versus piperacillin or tazobactam monotherapy. 51st ICAAC, Am Soc Microbiol. 2011, Abstract L1-1503a.Google Scholar
  16. 16.
    Burgess DS, Summers KK, Hardin TC. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. Clin Ther. 1999;21:1882–9.PubMedGoogle Scholar
  17. 17.
    Cafiso V, Bertuccio T, Spina D, et al. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS One. 2012;7:e29573.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Casapao AM, Davis SL, Barr VO, et al. A large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541–6.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013;57:4190–6.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Catchpole C, Andrews JM, Woodcock J, et al. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother. 1994;33:103–10.PubMedGoogle Scholar
  21. 21.
    Chemaly RF, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Med (Baltimore). 2009;88:211–20.Google Scholar
  22. 22.
    Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care. 2012;16:R113.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1996;40:1108–15.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother. 2013;57:3299–306.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17:1135–41.PubMedGoogle Scholar
  26. 26.
    Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720–6.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Dandekar PK, Maglio D, Sutherland CA, et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy. 2003;23:988–91.PubMedGoogle Scholar
  28. 28.
    de Aguiar CR, Mourão CI, Rocha MF, et al. Antifolates inhibit Cryptococcus biofilms and enhance susceptibility of planktonic cells to amphotericin B. Eur J Clin Microbiol Infect Dis. 2013;32:557–64.Google Scholar
  29. 29.
    de Pauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med. 1994;120:834–44.PubMedGoogle Scholar
  30. 30.
    del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis. 2001;33:1295–301.PubMedGoogle Scholar
  31. 31.
    Docobo-Pérez F, López-Cerero L, López-Rojas R, et al. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrob Agents Chemother. 2013;57:2109–13.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66 Suppl 4:7–15.Google Scholar
  33. 33.
    Durakovic N, Radojcic V, Boban A, et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011;50:1009–13.PubMedGoogle Scholar
  34. 34.
    Egerer G, Goldschmidt H, Salwender H, et al. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents. 2000;15:119–23.PubMedGoogle Scholar
  35. 35.
    EUCAST Antimicrobial wild type distributions of microorganisms. 2014. http://mic.eucast.org/Eucast2/. Accessed 1 Feb 2014.
  36. 36.
    Fainstein V, Bodey GP, Elting L, et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother. 1983;12(Suppl A):101–10.PubMedGoogle Scholar
  37. 37.
    Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194–9.PubMedGoogle Scholar
  38. 38.
    Feig PU, Mitchell PP, Abrutyn E, et al. Aminoglycoside nephrotoxicity: a double blind prospective randomized study of gentamicin and tobramycin. J Antimicrob Chemother. 1982;10:217–26.PubMedGoogle Scholar
  39. 39.
    Feld R, dePauw B, Berman S, et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol. 2000;18:3690–8.PubMedGoogle Scholar
  40. 40.
    Fleischhack G, Hartmann C, Simon A, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother. 2001;47:841–53.PubMedGoogle Scholar
  41. 41.
    Fraschini F, Scaglione F, Falchi M, et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother. 1990;2:171–7.PubMedGoogle Scholar
  42. 42.
    Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.PubMedGoogle Scholar
  43. 43.
    Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol. 1995;13:165–76.PubMedGoogle Scholar
  44. 44.
    Fugate JE, Kalimullah EA, Hocker SE, et al. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013;17:R264.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Fujisawa Y, Oyake T, Mine T, et al. Doripenem versus meropenem for empirical antimicrobial therapy in high risk febrile neutropenic patients with hematological malignancies: a randomized, controlled trial. ASH 2013 Annual Meeting Abstracts. Blood. 2013;122:4716.Google Scholar
  46. 46.
    Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;(1):CD004386.Google Scholar
  47. 47.
    Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–94.PubMedCentralPubMedGoogle Scholar
  48. 48.
    Ghehi MT, Rezaee S, Hayatshahi A, et al. Vancomycin pharmacokinetic parameters in patients undergoing hematopoietic stem cell transplantation (HSCT). Int J Hematol Oncol Stem Cell Res. 2013;7:1–9.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Gibson J, Date L, Joshua DE, et al. A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin. Aust N Z J Med. 1989;19:417–25.PubMedGoogle Scholar
  50. 50.
    Goldberg E, Bishara J. Contemporary unconventional clinical use of co-trimoxazole. Clin Microbiol Infect. 2012;18:8–17.PubMedGoogle Scholar
  51. 51.
    Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007;51:1905–11.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Hachem RY, Hicks K, Huen A, et al. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis. 2003;37:e8–11.PubMedGoogle Scholar
  53. 53.
    Haeseker M, Stolk L, Nieman F, et al. The ciprofloxacin target AUC: MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. Br J Clin Pharmacol. 2013;75:180–5.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis. 1997;24:810–5.PubMedGoogle Scholar
  55. 55.
    Imran H, Tleyjeh IM, Arndt CA, et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis. 2008;27:53–6.PubMedGoogle Scholar
  56. 56.
    Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597–607.PubMedGoogle Scholar
  57. 57.
    Jaruratanasirikul S, Limapichat T, Jullangkoon M, et al. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. Int J Antimicrob Agents. 2011;38:231–6.PubMedGoogle Scholar
  58. 58.
    Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother. 2005;49:1337–9.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Jean SS, Lee WS, Bai KJ, et al. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007. J Microbiol Immunol Infect. 2013. pii: S1684–1182(13)00118–7. doi:  10.1016/j.jmii.2013.07.002. [Epub ahead of print].
  60. 60.
    Joshi L, Taylor SR, Large O, et al. A case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic leukemia. Clin Infect Dis. 2009;48:e73–4.PubMedGoogle Scholar
  61. 61.
    Kahan FM, Kropp H, Sundelof JG, et al. Thienamycin: development of imipenem-cilastatin. J Antimicrob Chemother. 1983;12(Suppl D):1–35.PubMedGoogle Scholar
  62. 62.
    Kalil AC. Is cefepime safe for clinical use? A Bayesian viewpoint. J Antimicrob Chemother. 2011;66:1207–9.PubMedGoogle Scholar
  63. 63.
    Kern WV, Cometta A, de Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the EORTC. N Engl J Med. 1999;341:312–8.PubMedGoogle Scholar
  64. 64.
    Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy – EORTC Infectious Diseases Group Trial X. J Clin Oncol. 2013;31:1149–56.PubMedGoogle Scholar
  65. 65.
    Kim PW, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 2010;51:381–9.PubMedGoogle Scholar
  66. 66.
    Klinker H, Langmann P, Zilly M, et al. Drug monitoring during the treatment of AIDS-associated Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole. J Clin Pharm Ther. 1998;23:149–54.PubMedGoogle Scholar
  67. 67.
    Kullar R, Casapao AM, Davis SL, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013;68:2921–6.PubMedCentralPubMedGoogle Scholar
  68. 68.
    Kuti JL, Nightingale CH, Knauft RF, et al. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther. 2004;26:493–501.PubMedGoogle Scholar
  69. 69.
    Kwon KT, Cheong HS, Rhee JY, et al. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial. Jpn J Clin Oncol. 2008;38:49–55.PubMedGoogle Scholar
  70. 70.
    Lai CC, Sheng WH, Wang JT, et al. Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis. 2013;13:66.PubMedCentralPubMedGoogle Scholar
  71. 71.
    Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M, et al. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother. 2007;51:3290–7.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Lee LS, Kinzig-Schippers M, Nafziger AN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis. 2010;68:251–8.PubMedGoogle Scholar
  73. 73.
    Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer. 2006;107:1743–51.PubMedGoogle Scholar
  74. 74.
    Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37:415–9.PubMedGoogle Scholar
  75. 75.
    Luque S, Grau S, Valle M, et al. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant acinetobacter baumannii. Int J Antimicrob Agents. 2013;42:178–81.PubMedGoogle Scholar
  76. 76.
    MacVane SH, Kuti JL, Nicolau DP. Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents. 2014;43:105–13.PubMedGoogle Scholar
  77. 77.
    Manji A, Lehrnbecher T, Dupuis LL, et al. A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer. 2012;20:2295–304.PubMedGoogle Scholar
  78. 78.
    Mareville J, Gay J, Cliquennois E, et al. Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients. Scand J Infect Dis. 2012;44:398–401.PubMedGoogle Scholar
  79. 79.
    Martínez JA, Cobos-Trigueros N, Soriano A, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010;54:3590–6.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Mavros MN, Polyzos KA, Rafailidis PI, et al. Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:251–9.PubMedGoogle Scholar
  81. 81.
    McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–51.PubMedGoogle Scholar
  82. 82.
    Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010;54:1742–8.PubMedCentralPubMedGoogle Scholar
  83. 83.
    Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37:645–63.PubMedGoogle Scholar
  84. 84.
    Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Med Clin North Am. 2011;95:723–42.PubMedGoogle Scholar
  85. 85.
    Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27:1189–97.PubMedGoogle Scholar
  86. 86.
    Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013;(6):CD003038.Google Scholar
  87. 87.
    Paul M, Yahav D, Bivas A, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010;(11):CD005197.Google Scholar
  88. 88.
    Pea F, Viale P, Damiani D, et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother. 2005;49:3550–3.PubMedCentralPubMedGoogle Scholar
  89. 89.
    Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986;315:552–8.PubMedGoogle Scholar
  90. 90.
    Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53:3430–6.PubMedCentralPubMedGoogle Scholar
  91. 91.
    Poulikakos P, Falagas ME. Aminoglycoside therapy in infectious diseases. Expert Opin Pharmacother. 2013;14:1585–97.PubMedGoogle Scholar
  92. 92.
    Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11:425–34.PubMedGoogle Scholar
  93. 93.
    Rangaraj G, Granwehr BP, Jiang Y, et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer. 2010;116:967–73.PubMedGoogle Scholar
  94. 94.
    Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J. 1996;15:949–54.PubMedGoogle Scholar
  95. 95.
    Rigge DC, Jones MF. Shelf lives of aseptically prepared medicines – stability of piperacillin/tazobactam in PVC and non-PVC bags. J Pharm Biomed Anal. 2005;39:339–43.PubMedGoogle Scholar
  96. 96.
    Rodríguez-Baño J, Navarro MD, Retamar P, et al. β-lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54:167–74.PubMedGoogle Scholar
  97. 97.
    Rodríguez-Baño J, Oteo J, Ortega A, et al. Epidemiological and clinical complexity of amoxicillin-clavulanate-resistant Escherichia coli. J Clin Microbiol. 2013;51:2414–7.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Rolston KV, Besece D, Lamp KC, et al. Daptomycin use in neutropenic patients with documented gram-positive infections. Support Care Cancer. 2014;22:7–14.PubMedGoogle Scholar
  99. 99.
    Rolston KV, McConnell SA, Brown J, et al. Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry. Clin Adv Hematol Oncol. 2010;8:249–56.PubMedGoogle Scholar
  100. 100.
    Ryzner KL. Evaluation of aminoglycoside clearance using the modification of diet in renal disease equation versus the Cockcroft-Gault equation as a marker of glomerular filtration rate. Ann Pharmacother. 2010;44:1030–7.PubMedGoogle Scholar
  101. 101.
    Safdar A, Rolston KV. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer. 2006;106:1815–20.PubMedGoogle Scholar
  102. 102.
    Schentag JJ, Plaut ME, Cerra FB. Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother. 1981;19:859–66.PubMedCentralPubMedGoogle Scholar
  103. 103.
    Shea KM, Cheatham SC, Smith DW, et al. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother. 2009;43:1747–54.PubMedGoogle Scholar
  104. 104.
    Smith PF, Birmingham MC, Noskin GA, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant gram-positive infections in cancer patients with neutropenia. Ann Oncol. 2003;14:795–801.PubMedGoogle Scholar
  105. 105.
    Stein GE, Throckmorton JK, Scharmen AE, et al. Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. J Antimicrob Chemother. 2013;68:2852–8.PubMedGoogle Scholar
  106. 106.
    Stephens C, López-Nevot M, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013;8:e68111.PubMedCentralPubMedGoogle Scholar
  107. 107.
    Thabet F, Al Maghrabi M, Al Barraq A, et al. Cefepime-induced nonconvulsive status epilepticus: case report and review. Neurocrit Care. 2009;10:347–51.PubMedGoogle Scholar
  108. 108.
    van de Wetering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer. 2005;41:1372–82.PubMedGoogle Scholar
  109. 109.
    Veeraraghavan B. Newer β-lactam and β-lactamase inhibitor combinations available in India: consensus and controversies. Indian J Med Microbiol. 2011;29:315–6.PubMedGoogle Scholar
  110. 110.
    Velkov T, Roberts KD, Nation RL, et al. Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics. Future Microbiol. 2013;8:711–24.PubMedGoogle Scholar
  111. 111.
    Vesole DH, Oken MM, Heckler C, et al. Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study. Leukemia. 2012;26:2517–20.PubMedGoogle Scholar
  112. 112.
    Viaene E, Chanteux H, Servais H, et al. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46:2327–32.PubMedCentralPubMedGoogle Scholar
  113. 113.
    Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect. 2006;12:212–6.PubMedGoogle Scholar
  114. 114.
    Wolfensberger A, Sax H, Weber R, et al. Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: influence on cumulative hospital antibiograms. PLoS One. 2013;8:e79130.PubMedCentralPubMedGoogle Scholar
  115. 115.
    Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–48.PubMedGoogle Scholar
  116. 116.
    Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73:159–77.PubMedGoogle Scholar
  117. 117.
    Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther. 2012;10:459–73.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Medicine, Center for Infectious Diseases and Travel Medicine, IFB-Center for Chronic ImmunodeficiencyUniversity HospitalFreiburgGermany

Personalised recommendations